missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human IL-22BP Fc Chimera Avi-tag Protein
Description
Measured by its binding ability in a functional ELISA. When Recombinant Human IL-22 Protein (Catalog # 782-IL ) is coated at 0.500 μg/mL (100 μL/well), Biotinylated Recombinant Human IL-22BP Fc Chimera Avi-tag (Catalog # AVI1087) binds with an ED50 of 50.0-400 ng/mL.
Specifications
Specifications
| For Use With (Application) | Bioactivity |
| Formulation | Supplied as a 0.2 μm filtered solution in PBS with Trehalose. |
| Gene ID (Entrez) | 116379 |
| Molecular Weight (g/mol) | M.W. Observed: 73-82 kDa, under reducing conditions., M.W. Theoretical: 53 kDa |
| Quantity | 25 μg |
| Source | Human embryonic kidney cell, HEK293-derived human IL-22BP protein Human IL-22BP (Thr22-Pro231) (N-terminus) Accession # NP_851826.1 IEGRMD Human IgG1 (Pro100-Lys330) Avi-tag (C-terminus) |
| Storage Requirements | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after opening. 3 months, -20 to -70 °C under sterile conditions after opening. |
| Endotoxin Concentration | <0.10 EU per 1 μg of the protein by the LAL method. |
| Gene Alias | class II cytokine receptor, CRF2-10, CRF2-S1IL22BP, CRF2-X, Cytokine receptor class-II member 10, Cytokine receptor family 2 member 10, Cytokine receptor family type 2, soluble 1, IL-22 RA2, IL-22 receptor subunit alpha-2, IL22BP, IL-22BPCRF2X, IL22RA2, IL-22RA2, IL-22R-alpha-2, interleukin 22 receptor, alpha 2, interleukin 22-binding protein, interleukin-22 receptor subunit alpha-2, Interleukin-22-binding protein, MGC150509, MGC150510, zcytoR16 |
| Conjugate | Biotin |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?